Daniel Ness

2.5k citations

27 papers · 1.5k indexed · h-index 14

Impact in

Neurology top 5%
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurological disorders and treatments
Physiology top 5%
- Alzheimer's disease research and treatments

Papers in ⓘ

Neurology 8
- Parkinson's Disease Mechanisms and Treatments 6
- Neurological disorders and treatments 2
Clinical Biochemistry 3
- Advanced Glycation End Products research 2

Co-authors: Susan L. Schantz (2 shared papers)Larry G. Hansen (2 shared papers)Jamal Moshtaghian (1 shared paper)Patrick C. May (4 shared papers)Sue G. Griffith (3 shared papers)Michael Grundman (3 shared papers)Dale B. Schenk (3 shared papers)Susanne Ostrowitzki (3 shared papers)
Journals: Alzheimer s & Dementia (5 papers)Mycopathologia (2 papers)Toxicological Sciences (2 papers)Neurobiology of Aging (2 papers)Clinical Neuropharmacology (1 paper)
Partner nations: United States Switzerland Germany

In The Last Decade

Daniel Ness

27 papers receiving 1.4k citations

Peers

Countries citing papers authored by Daniel Ness

Since Specialization

Citations

This map shows the geographic impact of Daniel Ness's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Ness with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Ness more than expected).

Fields of papers citing papers by Daniel Ness

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Ness. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Ness. The network helps show where Daniel Ness may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Ness, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Ness Line = papers co-authored together Daniel Ness links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β Journal of Neuroscience ·Margaret M. Racke, Laura Boone, Deena L. Hepburn, Maia Parsadainian, Matthew T. Bryan, Daniel Ness, Kathy S. Piroozi, William H. Jordan, Donna D. Brown, Wherly P. Hoffman, David M. Holtzman, Kelly R. Bales, Bruce D. Gitter, Patrick C. May, Steven M. Paul, Ronald B. DeMattos	2005	261
2	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease JAMA Neurology ·Joseph Jankovic, Ira Goodman, Beth Safirstein, Tonya Marmon, Dale B. Schenk, Martin Koller, Wagner Zago, Daniel Ness, Sue G. Griffith, Michael Grundman, Jay Soto, Susanne Ostrowitzki, Frank Boess, Meret Martin‐Facklam, Joseph F. Quinn, Stuart Isaacson, Omid Omidvar, Aaron Ellenbogen, Gene G. Kinney	2018	224
3	First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers Movement Disorders ·Dale B. Schenk, Martin Koller, Daniel Ness, Sue G. Griffith, Michael Grundman, Wagner Zago, Jay Soto, George Atiee, Susanne Ostrowitzki, Gene G. Kinney	2016	185
4	Effects of perinatal exposure to specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat Toxicology Letters ·Daniel Ness, Susan L. Schantz, Jamal Moshtaghian, Larry G. Hansen	1993	181
5	Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers Clinical Neuropharmacology ·Eric Siemers, Michael Skinner, Robert A. Dean, Celedon Gonzales, Julie Satterwhite, Martin R. Farlow, Daniel Ness, Patrick C. May	2005	171
6	Characterization of fumonisin toxicity in orally and intravenously dosed swine Mycopathologia ·Wanda M. Haschek, Gideon K. Motelin, Daniel Ness, K. Harlin, W. F. Hall, R. F. Vesonder, Robert E. Peterson, Val R. Beasley	1992	163
7	Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis PLoS ONE ·Daniel Ness, Zhao Ren, Shyra J. Gardai, Douglas Sharpnack, Victor J. Johnson, Richard Brennan, Elizabeth Brigham, Andrew Olaharski	2013	65
8	Temporal and dose-response features in swine fed corn screenings contaminated with fumonisin mycotoxins Mycopathologia ·Gideon K. Motelin, Wanda M. Haschek, Daniel Ness, W. F. Hall, K. Harlin, David J. Schaeffer, Val R. Beasley	1994	57
9	The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo Blood ·Jan Endell, Rainer Boxhammer, Cornelia Wurzenberger, Daniel Ness, Stefan Steidl	2012	31
10	PCB congeners in the rat brain: Selective accumulation and lack of regionalization Journal of Toxicology and Environmental Health ·Daniel Ness, Susan L. Schantz, Larry G. Hansen	1994	30
11	P2-053 Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months Neurobiology of Aging ·Daniel Ness, Leonard N. Boggs, Deena L. Hepburn, Bruce D. Gitter, Gerald G. Long, Patrick C. May, Kathy S. Piroozi, Kenneth A. Schafer, Zhixiang Yang	2004	26
12	Effects of 3-Iodo-?-tyrosine, a Tyrosine Hydroxylase Inhibitor, on Eye Pigmentation and Biogenic Amines in the Planarian,Dugesia dorotocephala Fundamental and Applied Toxicology ·Daniel Ness	1996	18
13	UTI in kidney transplant World Journal of Urology ·Daniel Ness, Jonathon Olsburgh	2019	15
14	Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance Regulatory Toxicology and Pharmacology ·Joel P. Bercu, Wherly P. Hoffman, Cindy Lee, Daniel Ness	2008	14
15	Pharmacological inhibition of Polo Like Kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei Toxicology and Applied Pharmacology ·Kent Fitzgerald, Marcelle Bergeron, C O Willits, Simeon Bowers, Danielle L. Aubele, Erich Goldbach, George Tonn, Daniel Ness, Andrew Olaharski	2013	9
16	P1‐017: Comparison of cisternal and lumbar cerebrospinal fluid amyloid‐beta concentrations following oral administration of LY450139 dihydrate to Beagle dogs Alzheimer s & Dementia ·Patrick J. Cocke, Leonard N. Boggs, Daniel Ness, Patrick C. May	2008	7
17	P4-358 In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and the selective exacerbation of CAA-associated microhemorrhage Neurobiology of Aging ·Ronald B. DeMattos, Laura Boone, Deena L. Hepburn, Maia Parsadanian, Matthew T. Bryan, Daniel Ness, Kathy S. Piroozi, David M. Holtzman, Kelly R. Bales, Bruce D. Gitter, Steven M. Paul, Margaret M. Racke	2004	6
18	Spatial Learning Deficits in Adult Rats Exposed to ortho-Substituted PCB Congeners during Gestation and Lactation Toxicological Sciences ·Susan Schantz, JAMAL MOSHTAGHIAN, Daniel Ness	1995	4
19	P3‐322: Effects of single and multiple dose oral administration of ELND006, a novel APP‐selective gamma‐secretase inhibitor, on amyloid‐β concentrations in the brain and CSF of cynomolgus monkeys Alzheimer s & Dementia ·Elizabeth Brigham, Kevin P. Quinn, Ruth Motter, Wherly P. Hoffman, Erich Goldbach, Dora Kholodenko, Grace Kwong, Chris Willits, Gary D. Probst, Jane M. Gunther, Eric Adams, John‐Michael Sauer, Gene G. Kinney, Daniel Ness	2010	4
20	Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease Parkinsonism & Related Disorders ·Joseph Jankovic, Ira Goodman, Beth Safirstein, Dale B. Schenk, Gene G. Kinney, M. Köller, Daniel Ness, Sue G. Griffith, Michael Grundman, Jorge A. Soto, Susanne Ostrowitzki, Frank Boess, Meret Martin‐Facklam, Joseph F. Quinn, S.H. Issacson, Danna Jennings, Omid Omidvar, Aaron Ellenbogen	2018	4

About Daniel Ness

Daniel Ness is a scholar working on Neurology, Clinical Biochemistry, Transplantation, Cellular and Molecular Neuroscience and Small Animals, having authored 27 papers that have together received 1.5k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (6 papers), Parkinson's Disease Mechanisms and Treatments (6 papers), Nuclear Receptors and Signaling (3 papers), Carcinogens and Genotoxicity Assessment (3 papers), Computational Drug Discovery Methods (2 papers), Advanced Glycation End Products research (2 papers), Neurological disorders and treatments (2 papers) and Effects and risks of endocrine disrupting chemicals (2 papers). The work is most often cited by research in Neurology (425 citations), Neurology (230 citations), Physiology (579 citations), Biological Psychiatry (39 citations) and Cellular and Molecular Neuroscience (280 citations). Daniel Ness has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Susan L. Schantz, Larry G. Hansen, Jamal Moshtaghian, Patrick C. May, Sue G. Griffith, Michael Grundman, Dale B. Schenk, Susanne Ostrowitzki, Gene G. Kinney and Wagner Zago. Their work appears in journals such as Alzheimer s & Dementia, Mycopathologia, Toxicological Sciences, Neurobiology of Aging and Clinical Neuropharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact